Depression as a Prodromal Symptom of Pancreatic Cancer: A Narrative Review
Open Access
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, typically diagnosed at an advanced stage. The identification of prodromal symptoms could support earlier detection. Among these, depression is frequently reported, raising the question of whether it may represent not only a reactive response but also a paraneoplastic manifestation. Methods: We conducted a narrative review of clinical, epidemiological and biological literature published between 1988 and 2025. Searches were performed in PubMed/MEDLINE, Scopus, and Web of Science using predefined keywords related to pancreatic cancer, depression, prodromal symptoms, cytokines, and the kynurenine pathway. Eligible studies included clinical cohorts, population-based analyses, biological investigations, and case reports exploring the temporal or mechanistic link between depression and PDAC. Results: A substantial proportion of patients (10–20%) exhibit depressive symptoms in the months preceding the clinical diagnosis of pancreatic cancer. In several cases, depression occurs independent of weight loss and new-onset diabetes. Biological evidence highlights the involvement of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α), NF-κB signaling, and activation of the tryptophan–kynurenine pathway (IDO), suggesting a link between tumor-related processes and mood alterations. These mechanistic findings are actually hypothesis-generating, deriving mainly from small clinical cohorts and preclinical models. Clinically, depression is associated with reduced adherence to treatment, poorer quality of life, and shorter survival. However, no specific depressive phenotype has been identified. Conclusions: Depression may represent a potential prodromal symptom of pancreatic cancer, reflecting systemic biological processes as well as psychological reactions. Its utility as a standalone marker remains limited; future studies should integrate psychiatric, clinical and biological biomarker assessments to enhance early clinical diagnosis.Keywords
This publication has 39 references indexed in Scilit:
- Radiation enteropathy‐related depression: A neglectable course of disease by gut bacterial dysbiosisCancer Medicine, 2024
- Health‐related quality of life and survival outcomes for patients with major depressive disorder and anxiety: A longitudinal study in pancreatic ductal adenocarcinomaCancer Medicine, 2023
- Prodromal depression and anxiety are associated with worse treatment compliance and survival among patients with pancreatic cancerPsycho-Oncology, 2022
- Association of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancerHPB, 2021
- The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet Gastroenterology & Hepatology, 2019
- Depression, cytokines, and pancreatic cancerPsycho-Oncology, 2013
- The effect of depression on stage at diagnosis, treatment, and survival in pancreatic adenocarcinomaSurgery, 2012
- A Meta-Analysis of Cytokines in Major DepressionBiological Psychiatry, 2010
- Mechanisms of interferon-alpha-induced depressive symptomsActa Neuropsychiatrica, 2002
- Depression and pancreatic cancerJournal of Pain and Symptom Management, 1988